SYNTHOS RESEARCH

Keurig Dr Pepper KDP

Consumer Defensive · Beverages - Non-Alcoholic · Synthos Deep Dive · 2026-07-03

$33.30
Hold
Risk 5Growth 5Exponential 3Fair value $34 $26–$44

At a glance

VerdictHold — systematic Synthos tier
Price (2026-07-02)$33.30 · market cap ~$45.3B
Synthos scores (0–10)Downside Risk 5 · Growth Quality 5 · Exponential Potential 3
Synthos fair value (base case)~$34+2% · full range $26 (bear) – $44 (bull)
Street consensus$33.40 (high $38 / low $28; 16 Buy · 12 Hold · 0 Sell) — context, not our anchor
Valuation24.7× trailing EPS · 14.6× FY26E · 13.2× FY27E · 10.6× FY30E · EV/S 4.1× · EV/EBITDA 17.3×
Exponential Potential3/10 · Low — headline ~15% fwd EPS CAGR is mostly acquisition, organic single-digit; a mature category caps the upside
TechnicalsConstructive — $33.30, −5.4% off 52-wk high, above 50/200-DMA, RSI 67, but −0.8% 12-mo vs SPY +21% / QQQ +30%
ConvictionNone — 0 expert voices, 0 traceable claims in the Synthos KB; this call rests entirely on the numbers
Position sizingIf owned: small defensive/income satellite, ~1–2%, not a core growth holding
Next catalyst2026-08-06 Q2'26 earnings (Street EPS $0.55, revenue ~$7.25B)
Single biggest riskA leveraged, transformative coffee acquisition + planned split — integration and balance-sheet risk on a business already carrying ~$15B net debt

One-line thesis. KDP is a well-run, low-beta beverage staple that gushes cash and pays a ~2.8% dividend, but it is only fairly priced, its returns on capital are pedestrian (ROIC ~4%), and its next chapter is a debt-funded coffee mega-deal and corporate split — so the honest verdict is Watch: own it for income and stability if you must, but there is no margin of safety and no exponential upside here.

◆ Synthos call — Hold KDP is a solid business largely reflected at ~$34 — fine to keep, no reason to chase; it gets interesting again below ~$29.
Downside Risk (lower = safer)
5/10 · Moderate
Low beta 0.42 & defensive demand, but ~3.6× net-debt/EBITDA, 60% of assets in goodwill/intangibles, and a debt-funded transformation in flight.
Growth Quality
5/10 · Moderate
Headline 15% fwd EPS CAGR is mostly acquisition, not organic; ROIC ~4% and 54% gross margin are pedestrian; moat is real but slow.
Exponential Potential
3/10 · Low
Mature staples compounder — growth is inorganic and decelerating on an organic basis; a $45B cap in a saturated category is no multibagger.
⚖ Reverse-DCF cross-check Market-implied growth ≈ 13%/yr To justify today’s $33, earnings would have to compound roughly 13% a year for 10 years (9% discount rate). Analysts forecast ~10%/yr, so the market is pricing in MORE than what the Street expects.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

In plain English

Keurig Dr Pepper makes drinks you know: Dr Pepper, Snapple, 7UP, Canada Dry, Mott's, and the Keurig K-Cup coffee pods and machines. It is a big, steady "consumer staples" company — people buy soda and coffee in good times and bad, so the sales are dependable and the stock doesn't swing much.

Is the stock cheap or expensive? It is priced about right — not a bargain, not obviously overpriced. You are paying a fair price for a slow, dependable grower that pays a ~2.8% dividend (about $0.92 a year per share). Our verdict is Watch: there's nothing wrong with the company, but there's no obvious bargain and no fast-growth story, so most investors can simply keep an eye on it rather than rush to buy.

Here's what our three scores mean in everyday terms:

The one big worry: KDP is spending heavily (and borrowing) to buy a giant coffee company and then split itself into two companies. If that goes badly, the debt and disruption could hurt.


Price & moving averages 12 months · 50 & 200-day averages · 52-week range

2527303336Jul '25Sep '25Nov '25Feb '26Apr '26Jul '2652w hi $35Price 3350-DMA 30200-DMA 2852w lo $25

Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

2327313539Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26Price 3320-day avg 32

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

705030Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26RSI 67.5

Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 67.

MACD 12 / 26 / 9 · trend & momentum

0Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26MACD 0.9signal 0.8

Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago

718599112126Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26S&P 500 120XLP (sector) 103KDP 98

Solid = KDP · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

09192838$15BFY23EPS $2$15BFY24EPS $2$16BFY25EPS $2$26BFY26EEPS $2$30BFY27EEPS $3$31BFY28EEPS $3$32BFY29EEPS $3$33BFY30EEPS $3

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$33.30
Market cap$45B
P/E trailing
P/E FY26E / FY27E15× / 13×
EV / Sales4.1×
EV / EBITDA17.3×
Gross margin53.8%
Net margin10.8%
Dividend yield2.76%
Beta0.424
52-wk range$25 – $35
RSI(14)67
50 / 200-DMA$30 / $28
12-mo return+-1% (SPY +21%)
Street target$33 ($28–$38)
Analyst grades16 Buy · 12 Hold · 0 Sell
FMP ratingB
Next earnings2026-08-05

What the experts actually said 0 traceable claims on KDP · showing the highest-conviction voices

Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.

1. What it is

Keurig Dr Pepper (NASDAQ: KDP) is a North American beverage powerhouse formed by the 2018 merger of Keurig Green Mountain and Dr Pepper Snapple. It sells across four reporting units — Coffee Systems (Keurig brewers + K-Cup pods), Packaged Beverages (its own bottled/canned brands plus contract manufacturing and partner distribution), Beverage Concentrates (Dr Pepper, Canada Dry, A&W, 7UP, Sunkist, Snapple, Mott's, Bai and more), and Latin America Beverages. Headquarters in Frisco, TX; ~29,000 employees; CEO Timothy Cofer. Fiscal year ends December 31.

Revenue mix (FY2025, from filings):

The strategic pivot to understand: KDP has announced a transformative expansion of its coffee business (a large coffee acquisition) and a plan to separate into two independent companies (a global coffee company and a North American beverages company). This is why the forward analyst estimates show revenue stepping up from ~$16.6B to ~$26B+ — that jump is largely inorganic (acquired scale), not underlying volume growth. Read the forward numbers with that caveat throughout.

2. The expert thesis (traceable)

There is no expert coverage of KDP in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0. No independent analyst or investor in our tracked panel has a distilled, traceable claim on this name.

That is stated plainly and by design: Synthos will never fabricate conviction. Where the KB is silent, we say so and fall back to fundamentals and quant. Everything in this note is derived from reported financials, FMP analyst consensus (labeled as estimates), and price/technical data — not from expert conviction. Readers should weight this note accordingly: it is a quantitative and fundamental read, not a high-conviction, expert-corroborated call like our flagship names.

3. Synthos scores

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score0–10The read
Downside Risk (lower = safer)5 · ModerateBeta 0.42 and defensive, non-cyclical demand cushion the downside, but ~$15.1B net debt (~3.6× FY25 EBITDA), 60% of assets in goodwill/intangibles, and a debt-funded acquisition + split in flight add balance-sheet and execution risk. Only fairly valued, so limited valuation cushion too.
Growth Quality5 · Average54% gross / 24% EBITDA margins are solid but unremarkable; ROIC ~4% and ROE ~7% are below what a great compounder shows. Headline ~15% forward EPS CAGR is mostly acquisition-driven — organic growth is mid-single-digit.
Exponential Potential3 · LowSoda and single-serve coffee are mature, saturated categories. Growth is inorganic and decelerating organically; a $45B cap with no large untapped TAM is structurally not a multibagger.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. Because the acquisition/split reshapes the share count and capital structure, we anchor the multiple to near-term (FY26–27E) earnings power rather than the post-deal FY30 figure.

CaseKey assumptionsFair value
BullCoffee deal integrates cleanly; the two-company split unlocks a sum-of-parts re-rating; organic LRB momentum continues. FY27E EPS beats toward ~$2.65; market pays a ~17× premium staples multiple.~$44 (+32%)
Base (our anchor)Estimates roughly hit — FY27E EPS ~$2.52; a mid-single-digit organic compounder with a mature coffee arm earns a ~13.5× multiple in line with slow-growth staples peers.~$34 (+2%)
BearIntegration friction, incremental leverage strains the dividend, or coffee volumes keep sliding. FY27E EPS misses toward ~$2.30; multiple de-rates to ~11× on balance-sheet worry.~$26 (−22%)

Synthos fair value = the base case, ~$34 (+2%), with the full $26–$44 span as the honest range. This anchor sits essentially on top of the Street's $33.40 consensus — which is itself the point: at today's price the risk/reward is roughly symmetric and offers no margin of safety. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). KDP is neither an exponential nor an elite compounder — it is a mature staples cash machine:

Exponential Potential: Low (3/10). Own KDP, if at all, for stability and income — not for growth and certainly not for a multibagger. This is the honest opposite of a flagship next-exponential.

5. Financials (real numbers — FMP annual/quarterly)

6. Valuation — priced in or room?

KDP screens as fairly valued, not cheap and not expensive. Trailing 24.7× EPS, 4.1× EV/sales, 17.3× EV/EBITDA, ~2.8% dividend yield. On forward consensus the P/E compresses to 14.6× (FY26E) → 13.2× (FY27E) → 10.6× (FY30E) — but remember that compression is powered largely by acquired earnings, so it flatters the organic multiple. Stripped of the deal, KDP trades at a normal staples multiple for a normal staples grower. The FMP letter rating is B (overall score 3/5), with its weakest sub-scores on debt-to-equity and P/E — consistent with our read. Street targets (context): consensus $33.40, high $38, low $28, with a Buy/Hold split (16 Buy, 12 Hold, no Sells). Our base-case fair value (~$34) essentially matches consensus, which is exactly why the verdict is Watch: at $33.30 you are paying fair value with no discount, so the reward for the transformation risk is thin.

7. Technicals (computed from EOD price history)

8. Moat & competitive position

KDP's moat is real but narrow: (1) iconic brands with durable shelf presence (Dr Pepper is a genuine share-gainer in US carbonated soft drinks; Snapple, Canada Dry, Mott's, 7UP anchor the portfolio); (2) the Keurig razor-and-blades coffee ecosystem — an installed base of brewers that pulls recurring high-margin K-Cup pod sales, though the pod patent cliff long ago opened the door to private-label competition; (3) distribution scale across DSD and warehouse channels. The weaknesses: it is a clear #3 behind Coca-Cola and PepsiCo in beverages and faces private-label and single-serve-coffee competition (Nespresso, store brands) on the pod side. Returns on capital (~4% ROIC) confirm the moat monetizes at ordinary, not premium, rates.

Peer set (market cap): the FMP peer list skews to consumer-staples adjacents rather than pure beverage rivals — Coca-Cola Europacific Partners $47B, Ambev $48B, Sysco $41B, Kimberly-Clark $38B, Kenvue $38B, Hershey $37B, Kroger $36B, Estée Lauder $30B, Kellanova $29B, Target $59B. The more relevant strategic comps (not in the FMP list) are Coca-Cola and PepsiCo, both far larger and higher-return. Within this staples cohort KDP is mid-pack on growth and multiple.

9. Management, capital allocation & guidance

10. Catalysts & what to watch

Thesis tripwires (what would change the call): integration missteps or a deal price that pushes net-debt/EBITDA meaningfully above ~4×; two consecutive quarters of organic volume declines; FCF falling below dividend coverage; or a de-rating that finally opens a real valuation discount (which would flip Watch → Buy).

11. Key risks

12. Verdict, position sizing & monitoring

Watch. KDP is a competently run, low-beta beverage staple that produces dependable cash flow and a ~2.8% dividend — but it is only fairly priced (our ~$34 base case ≈ the $33.30 quote ≈ the $33.40 Street consensus), its returns on capital are ordinary, its growth is largely inorganic and organically decelerating, and it is mid-way through a leveraged, transformative coffee acquisition and corporate split that adds real risk without an offsetting discount in the price. There is no expert conviction in the Synthos KB to lean on. That combination — good company, no bargain, no exponential upside, elevated near-term corporate risk — is the textbook definition of Watch, not Buy.


Provenance & disclosures